ABSTRACT Introduction. To identify melanoma patients at sufficiently low risk of nodal metastases who could avoid sentinel lymph node biopsy (SLNB), several statistical models have been proposed based upon patient/tumor characteristics, including logistic regression, classification trees, random forests, and support vector machines. We sought to validate recently published models meant to predict sentinel node status. Methods. We queried our comprehensive, prospectively collected melanoma database for consecutive melanoma patients undergoing SLNB. Prediction values were estimated based upon four published models, calculating the same reported metrics: negative predictive value (NPV), rate of negative predictions (RNP), and false-negative rate (FNR). Results. Logistic regression performed comparably with our data when considering NPV (89.4 versus 93.6%); however, the model's specificity was not high enough to significantly reduce the rate of biopsies (SLN reduction rate of 2.9%). When applied to our data, the classification tree produced NPV and reduction in biopsy rates that were lower (87.7 versus 94.1 and 29.8 versus 14.3, respectively). Two published models could not be applied to our data due to model complexity and the use of proprietary software. Conclusions. Published models meant to reduce the SLNB rate among patients with melanoma either underperformed when applied to our larger dataset, or could not be validated. Differences in selection criteria and histopathologic interpretation likely resulted in underperformance. Statistical predictive models must be developed in a clinically applicable manner to allow for both validation and ultimately clinical utility.
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Sentinel lymph node biopsy (SLNB) provides critical staging information for clinically node-negative melanoma patients and may have a therapeutic benefit. 1 For these reasons, SLNB has been widely accepted as a component of the surgical management of melanoma. 2 However, the procedure is not without controversy. 3, 4 Although the Multicenter Selective Lymphadenectomy Trial-I (MSLT-I) trial, which randomized clinically node-negative patients to wide excision alone versus wide excision with SLNB, suggested a potential therapeutic benefit for SLNB among the node-positive patients, overall the study demonstrated no survival benefit to the procedure. 1 One reason the MSLT-I trial likely failed to demonstrate any overall survival benefit to SLNB is that any therapeutic benefit is limited to patients harboring micrometastases, which is around 20% of patients with the present indications for SLNB. Improved patient selection, by increasing the fraction of patients found to have metastatic disease, would improve the relative therapeutic benefit of the procedure and minimize cost and morbidity. To that end, multiple groups, including ours, have retrospectively examined their SLN outcomes in an attempt to identify clinical and histopathologic features that may correlate with positive SLN. [5] [6] [7] [8] Some of these studies attempted to create statistical models with high accuracy for predicting SLN status. 8, 9 To identify patients at sufficiently low risk of nodal metastases to avoid the procedure, Mocellin et al. examined four predictive statistical models, focusing on negative predictive value (NPV), SLNB reduction rate (rate of negative predictions, RNP), and false-negative rate (FNR), or how many patients with positive biopsies were predicted to be negative by the model. 10 They reported predictive models that could identify approximately onequarter of patients who may be spared SLNB, with a falsenegative error rate of 1-2%. In their conclusion, the authors ask institutions involved in the management of melanoma to independently validate their models. In this study, we attempted to do just that.
METHODS
In the Mocellin paper, a sample of 1,132 melanoma patients from two institutions were used to construct four statistical models using logistic regression, classification trees, random forests, and support vector machines (SVM), with the intention of selecting models that allowed for significant reduction in the number of biopsies performed while incurring a minimum of false negatives. To validate these findings, after obtaining approval from the University of Michigan Institutional Review Board (IRB), we queried our comprehensive, prospectively collected melanoma database to identify consecutive melanoma patients 16 years of age and older who underwent SLNB at the University of Michigan.
Our SLNB technique has been previously published. 9 SLN specimens are fixed in 10% neutral-buffered formalin, serially sectioned longitudinally at 2-3-mm intervals, and entirely embedded in paraffin. Hematoxylin and eosin (H&E) staining is performed on two 5-lm-thick sections from each tissue block. In addition, four unstained serial sections are prepared for possible future immunohistochemical analysis. If SLN(s) are negative by routine light microscopy, immunohistochemical staining is routinely performed using antibodies to the melanoma markers Melan-A (1:12.5 dilution; DAKO Corporation, Carpinteria, CA) and S-100 protein (1:500 dilution; DAKO Corporation, Carpinteria, CA). Using information available from the Mocellin paper itself and/or the web address cited for supplementary material, we attempted to duplicate their statistical models, using our data with respect to outcome of interest [positive sentinel lymph node (PSLN)] and independent covariates, for the purpose of predicting the occurrence of PSLN. The covariates of interest included the following patient/tumor characteristics: patient age and gender, tumor thickness (Breslow depth), Clark level, regression, ulceration, histologic subtype, and mitotic index. To evaluate similarities and differences in the predictive ability of Mocellin's statistical models when applied to our data as compared with when applied to their data, we calculated the same metrics (NPV, RNP, and FNR) they had previously published. If data were missing, this was handled both by using only cases for which we had complete data and by employing multiple imputation using Imputation and Variance Estimation (IVEware) software. This free, downloadable software, maintained by researchers at the Survey Methodology Program, Survey Research Center at the University of Michigan, uses a multivariate sequential regression approach to impute missing values in analytical datasets. Multiple imputed datasets can be created, such that missing data are replaced by ''sensible'' guesses based upon the remainder of the patient's data. Multiple imputation methods can then be used to aggregate the estimates from the regression models from each of the imputed datasets. 11 Full details of the program and its uses can be found at http://www.isr.umich.edu/src/smp/ive/.
RESULTS
We identified 2,313 patients who underwent SLNB for melanoma between 1998 and 2009. The clinical and demographic characteristics are summarized in Table 1 , compared with the Mocellin data. There were several differences between the patient populations. Gender and age distribution were essentially the same. Although median Breslow thickness was similar, the data used by Mocellin et al. had a larger fraction of melanomas less than 1.0 mm in Breslow thickness than in our dataset (23.8 versus 10.5%). This likely reflects differences in the application of sentinel lymph node biopsy. Whereas they performed SLNB on patients with melanoma \1 mm if Clark level was IV or V or ulceration was present, we do not use Clark level as an indication for SLNB. Instead, we perform SLNB on melanoma \1 mm only in the presence of other adverse histologic features such as angiolymphatic invasion, ulceration, high mitotic rate, or young age, resulting in fewer patients with thin melanoma being mapped. The Mocellin population also has a higher fraction of Clark level II and III patients, whereas for patients for whom data were available, we had far fewer Clark level II and III melanomas. Complicating this was the undocumented Clark level for a fraction of our patients. We stopped routinely recording Clark level as it was not predictive of SLN status, however this variable appears in all of Mocellin et al.'s models. 5, 9 We therefore approached this in two ways: analyzing only cases for which we had complete data (1,667 subjects, or 72% of the original dataset), and employing multiple imputation using IVEware (version 0.2; Institute for Social Research, University of Michigan, 2010) in order to generate full datasets for further analysis. Other differences between our two datasets included a much higher rate of regression in the Mocellin data (nearly half of the patients compared with only 13.4%) and a higher mitotic rate among our patients, the latter likely reflecting our use of mitotic rate as a selection criteria for SLNB.
All patient/tumor characteristics selected for modeling by Mocellin et al. seemed to be of especially strong predictive value for their data. Of their four models, three (logistic, tree, and SVM) were, on the whole, largely similar both in terms of the set of variables they identified as significant as well as in their performance as measured by NPV (93.6, 94, and 93%, respectively), RNP (27.5, 29.8, and 30.1%, respectively), and FNR (1.8, 1.8, and 2.1%, respectively). However, the random forest seemed to perform somewhat better, with 97% NPV and false-negative rate (FNR) of 0.5%. This was achieved, however, at the cost of a lesser reduction in biopsies (RNP), at only 18%.
Logistic Regression
We began with what Mocellin et al. note is the simplest and most commonly applied model, logistic regression, for which the coefficients in the prediction model were given in their paper. We applied their model to our data twice, first using only patients for whom we had the full set of observations, then on data imputed using IVEware; there were only negligible differences in the results.
Using a cutoff value of 0.1 for the predicted probability to define cases as having a positive SNB at the individual level (not to be confused or aligned with the proportion of positivity at the population level), we found that the logistic model's performance with our data produced worse NPV yet better FNR. These results are presented in Table 2 . However, it seems that the model's specificity is not high enough to be efficient at reducing the rate of biopsies. Raising the probability cutoff to 0.2 lowers the NPV by a negligible amount, while lowering the cutoff to 0.05 has minimal impact on the already low false-negative rate and error rate, while lowering the number of SLNB cases potentially omitted.
Classification Tree
When evaluating their classification tree when applied to our data (Table 3 ) compared with applied to their data, the performance was reduced for two of three metrics. Comparing our metrics with theirs, the NPV was slightly lower and the RNP was substantially lower; however, the error rate was slightly lower for our data.
We also present in Tables 2 and 3 the sensitivity and specificity of the logistic and tree models applied to the Mocellin data and applied to our data. While the sensitivity and specificity of these models applied to our data were quite good, they were not quite as good as for these models applied to the Mocellin data.
Random Forest and SVM
Unfortunately, we were unable to validate the remaining two models, the random forest and SVM. These are sophisticated models, which if carefully constructed have the potential for superior performance; however, by their nature they cannot be summarized by a simple graph or equation. In the end, despite multiple correspondences with the authors, because of the complexity of the models in question, complicated by the use of proprietary software (DTREG), we could not apply these models to our data. This was especially disheartening because the random forest model was potentially the best of the four by Mocellin et al. metrics.
DISCUSSION
Breslow thickness is a validated and highly reproducible factor predictive of SLN status, thus SLNB is recommended in any melanoma patient with Breslow thickness C1.0 mm, resulting in a SLN positivity rate of 15-25%. 12 Several groups have attempted to identify clinicopathological features that may correlate with SLN positivity (Table 4) , typically with a goal of identifying adverse factors to select patients with thin melanomas for the procedure. Balch et al., 2 in arguing that SLNB should be the standard of care, state that the risk of nodal metastases should be sufficient to justify the procedure, and approximate this rate as C10%. It follows logically that, if there are adverse features that can identify patients with thin melanoma who should have the procedure (risk C10%), then it would also be ideal to identify a subset of patients with melanoma C1 mm, lacking those features and having a risk \10%, who do not need the procedure.
In 2006, we proposed this idea, based on logistic regression techniques showing the interactions between Breslow thickness, age, and mitotic rate on SLN positivity. 9 However, as Mocellin et al. correctly point out, our model was based on maximizing predictive accuracy, which may not be the ideal clinical criteria. Differentiating a 30% risk from a 50% risk is clinically irrelevant, as both would be recommended for SLNB. Models maximizing the negative predictive value would better select patients to avoid SLNB. Using data from two centers in Italy and Australia, they conclude that their models can spare a high percentage of patients from SLNB with a small error rate, and sought validation from other institutions.
We could apply the logistic regression and classification tree models to our data, although we found them less useful than reported. For the logistic model, the cutpoint for the predicted probability of PLSN was not stated by Mocellin et al., making exact comparison difficult. However, using a cutpoint of 0.1, the logistic regression model reduced the SLNB rate by 2.9% for University of Michigan (UM) data, far below the 27.5% reported by the Mocellin group. The classification tree had similar prediction metrics, although again the decrease in the fraction of patients recommended to undergo SLN was not as large. There is potential for this model; if applied prospectively to our data, there would have been a 14% reduction in SLNB, with a simultaneous reduction in FNR and no increase in error rate.
It is likely that the dissimilar performance is related to differences in the selection criteria used to recommend SLNB and thereby create the sample data on which their models are constructed. Mocellin et al. include patients with thin melanomas having Clark level of IV or V. This represents approximately one-fifth of their analyzed sample. However, at our institution, SLNB would not have been recommended for these patients in the first place, without additional worrisome characteristics. Therefore, the levels of reduction in SLNB reported by Mocellin et al. may be less significant when using data from institutions that already have a higher recommendation threshold for SLNB.
In attempting to validate these results, several additional issues related to predictive models in oncology became apparent. One important lesson in moving forward is to remember that, for these models to be clinically relevant, it is necessary for them to be available in a readily usable form, first for institutions to validate the results, and ultimately for clinicians. Despite multiple attempts, only one out of the four models (classification tree) could be exactly validated, with a second method, logistic regression, duplicated but with the probability cutpoint used for classification only estimated as it was not provided in the original published manuscript. The random forest and SVM methods could not be validated. These models are sophisticated, requiring specialized proprietary software, so the models are not readily generalizable. As the ultimate goal is to provide models applicable to a wide variety of data sources, consideration must be given to software availability. A number of R packages exist, for example, that allow for the creation and storage of such models. R is a freely available language and environment for statistical computing. Like commercial products such as SAS or STATA, R is a statistical analysis platform that is often used in the academic statistical and biostatistical communities. R packages are add-on features that expand the statistical application of the R program and can be freely downloaded at http://cran.r-project.org. Alternatively, a website can be established in which the user enters the patient characteristics and the website returns the prediction. A trivial exercise for logistic models and classification trees, this would require additional efforts for the complexity of the classification routines employed by random forests and support vector machine techniques. Another challenge to the creation and application of these predictive models is the variability in the interpretation of histopathologic features. The histopathologic interpretation of melanoma with evaluation of the prognostic parameters is the single most important factor in the selection criteria for SLNB. Accordingly, differences in datasets can often be traced to interinstitution differences in histologic interpretation. Regression emerged as one factor in selecting patients likely to be node negative. Regression was present in almost half of the patients in the Mocellin dataset, as compared with only 13% of our dataset. Among similar series, regression was only present in a small percentage of patients (between 7% and 18%). 5, 6, [13] [14] [15] [16] However, there is one outlier (28%). 7 The reported presence of regression in a larger proportion of cases in the Mocellin dataset likely reflects a lower histologic threshold or looser definition of regression. Early histologic evidence corresponds to approximately 4-6 high-power fields. If four high-power fields of melanoma are just randomly evaluated, it would not be unusual for not a single mitosis to be identified. At our institution, dermatopathologists specifically seek out mitotically active areas from which to obtain their count. Historically, our data have shown that even a single mitosis identified in the dermal invasive component of melanoma can stratify patients into a higher risk group for SLN positivity. 6 Thus, our dermatopathologists are sensitized to the prognostic and therapeutic implications between identifying no mitoses, which corresponds to the ''low'' category, versus finding even a solitary mitotic figure, which would then stratify to the ''medium'' mitotic index category.
In conclusion, the logistic regression and classification tree models reported by Mocellin et al. provided high sensitivity but low specificity when applied to our data, and had less impact on the reduction in the number of SLN performed than reported. While the logistic regression model has negligible impact on reducing SLNB, the classification tree model performed better. Differences in both selection criteria and the interpretation of histopathologic features likely contribute to variation in model performance. The random forest and SVM models were unable to be clinically validated.
